583. Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.
作者: Alain Combes.;Ouriel Saura.;Nicolas Nesseler.;Said Lebbah.;Bertrand Rozec.;Bruno Levy.;Jean-Luc Fellahi.;Antoine Beurton.;Simon Meslin.;Philippe Gaudard.;Adrien Bouglé.;André Vincentelli.;Romain Sonneville.;Guillaume Lebreton.;David Lévy.;Alexandre Ouattara.;Florence Tubach.; .
来源: JAMA. 2026年335卷1期60-69页
Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited.
589. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults.
Obesity is a chronic, relapsing disease affecting over 1 billion people worldwide, driving substantial morbidity, mortality, and economic burden. Glucagon-like peptide-1 therapies (GLP-1 therapies) provide clinically meaningful weight loss and broad metabolic benefits. In response to Member State requests, the World Health Organization (WHO) has issued guidelines for adults living with obesity.
590. Therapeutic Use of Cannabis and Cannabinoids: A Review.
Approximately 27% of adults in the US and Canada report having ever used cannabis for medical purposes. An estimated 10.5% of the US population reports using cannabidiol (CBD), a chemical compound extracted from cannabis that does not have psychoactive effects, for therapeutic purposes.
|